Analyst Price Targets — MLYS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 19, 2025 12:49 pm | — | Stifel Nicolaus | $52.00 | $37.00 | TheFly | Mineralys Therapeutics price target raised to $52 from $45 at Stifel |
| October 30, 2025 10:07 am | — | H.C. Wainwright | $52.00 | $40.14 | TheFly | Mineralys Therapeutics price target raised to $52 from $42 at H.C. Wainwright |
| May 14, 2025 12:07 pm | Seamus Fernandez | Guggenheim | $48.00 | $15.11 | TheFly | Mineralys Therapeutics price target lowered to $48 from $52 at Guggenheim |
| April 2, 2025 10:13 am | Matthew Caufield | H.C. Wainwright | $42.00 | $14.00 | TheFly | Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright |
| April 2, 2024 3:18 am | Richard Law | Goldman Sachs | $30.00 | $13.03 | StreetInsider | Goldman Sachs Starts Mineralys Therapeutics, Inc. (MLYS) at Buy, 'Upcoming Pivotal Results Could Surprise on the Upside' |
Latest News for MLYS
RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of…
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of…
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) was the recipient of some unusual options trading on Friday. Investors purchased 92,406 put options on the company. This represents an increase of approximately 3,057% compared to the average daily volume of 2,927 put options. Mineralys Therapeutics Price Performance NASDAQ: MLYS opened at $29.77 on Friday. Mineralys Therapeutics
The Dow is eyeing its best day in 10 months, as a bounce back in tech and software stocks lift Wall street
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MLYS.
U.S. House Trading
No House trades found for MLYS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.